These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 23224484)
1. Status epilepticus associated with dalfampridine in a patient with multiple sclerosis. de Gusmao CM; Ortega MR; Wallace DM J Neuropsychiatry Clin Neurosci; 2012; 24(4):E47-8. PubMed ID: 23224484 [No Abstract] [Full Text] [Related]
2. Dalfampridine (Ampyra) for MS. Med Lett Drugs Ther; 2010 Sep; 52(1347):73-4. PubMed ID: 20847716 [No Abstract] [Full Text] [Related]
3. De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. Panicucci E; Cohen M; Bourg V; Rocher F; Thomas P; Lebrun C Mult Scler; 2019 Apr; 25(4):618-621. PubMed ID: 30375922 [TBL] [Abstract][Full Text] [Related]
4. Dalfampridine: is the seizure risk greater than previously thought? Farag A; Averill A Am J Phys Med Rehabil; 2013 Jul; 92(7):635-6. PubMed ID: 23051757 [No Abstract] [Full Text] [Related]
5. 10 questions about 4-aminopyridine and the treatment of multiple sclerosis. Bever CT Neurologist; 2009 May; 15(3):161-2. PubMed ID: 19430274 [No Abstract] [Full Text] [Related]
6. 4-aminopyridine: new life for an old drug. Hauser SL; Johnston SC Ann Neurol; 2010 Jul; 68(1):A8-9. PubMed ID: 20583227 [No Abstract] [Full Text] [Related]
13. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Dunn J; Blight A Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605 [TBL] [Abstract][Full Text] [Related]
14. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances. Egeberg MD; Oh CY; Bainbridge JL Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001 [TBL] [Abstract][Full Text] [Related]
15. Dalfampridine approved for MS. Traynor K Am J Health Syst Pharm; 2010 Mar; 67(5):335. PubMed ID: 20172978 [No Abstract] [Full Text] [Related]
17. Assessment of the efficacy and safety of fampridine. Mejuto B; Castellano P; Castro C; López LM Farm Hosp; 2017 Mar; 41(2):283-291. PubMed ID: 28236802 [TBL] [Abstract][Full Text] [Related]
18. Assessing dalfampridine efficacy in the physician's office. Raffel JB; Malik O; Nicholas RS Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943 [TBL] [Abstract][Full Text] [Related]
19. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Blight AR; Henney HR; Cohen R Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911 [TBL] [Abstract][Full Text] [Related]
20. [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis]. Husseini L; Leussink VI; Kieseier BC; Hartung HP Nervenarzt; 2010 Feb; 81(2):203-11. PubMed ID: 20112006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]